JNJ logo

Johnson & Johnson

JNJ
Healthcare|Drug Manufacturers - General|US
$276.22
+3.90 (+1.43%)
DCF Value
$295.64
Graham Number
$70.20
Cash / Share
$7.04

Financials

Financial Snapshot

Market Cap
$664.95B
Enterprise Value
$692.69B
Revenue (TTM)
$99.33B
Net Income (TTM)
$16.09B
Cash & Investments
$17.23B
Net Cash
-$27.42B
Free Cash Flow (TTM)
$20.59B
Operating CF (TTM)
$26.16B
Debt/Equity
0.55

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$41.91B$18.30B$19.69B$19.29B$25.18B$31.61B$22.28B$22.93B$24.52B$20.10B$17.23B
Operating Cash Flow
$18.77B$21.06B$22.20B$23.42B$23.54B$23.41B$21.19B$22.79B$24.27B$24.53B$26.16B
Free Cash Flow
$15.54B$17.78B$18.53B$19.92B$20.19B$19.76B$17.18B$18.25B$19.84B$19.70B$20.59B
Capital Expenditure
-$3.23B-$3.28B-$3.67B-$3.50B-$3.35B-$3.65B-$4.01B-$4.54B-$4.42B-$4.83B-$5.57B
Financing Cash Flow
-$8.55B-$7.67B-$18.51B-$18.02B-$6.12B-$14.05B-$8.87B-$15.82B-$3.13B-$5.54B-$18.15B

R&D Spending

R&D (TTM)
$16.08B
R&D Intensity
16.2%
R&D Growth vs Prior
+9.7%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$71.89B$76.45B$81.58B$82.06B$82.58B$78.74B$79.99B$85.16B$88.82B$94.19B$99.33B
R&D Expense
$9.14B$10.59B$10.78B$11.36B$12.34B$14.28B$14.13B$15.09B$17.23B$14.66B$16.08B
R&D % of Revenue
12.7%13.9%13.2%13.8%14.9%18.1%17.7%17.7%19.4%15.6%16.2%
SG&A
$20.07B$21.52B$22.54B$22.18B$22.08B$20.12B$20.25B$20.11B$21.97B$23.68B$25.50B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$71.89B$76.45B$81.58B$82.06B$82.58B$78.74B$79.99B$85.16B$88.82B$94.19B$99.33B
Cost of Revenue
$21.79B$25.44B$27.09B$27.56B$28.43B$23.40B$24.60B$26.55B$27.47B$30.26B$30.98B
Gross Profit
$50.10B$51.01B$54.49B$54.50B$54.16B$55.34B$55.39B$58.61B$61.35B$63.94B$68.35B
R&D
$9.14B$10.59B$10.78B$11.36B$12.34B$14.28B$14.13B$15.09B$17.23B$14.66B$16.08B
SG&A
$20.07B$21.52B$22.54B$22.18B$22.08B$20.12B$20.25B$20.11B$21.97B$23.68B$25.50B
Operating Income
$20.89B$18.90B$21.18B$20.97B$19.73B$20.94B$21.01B$23.41B$22.15B$25.60B$25.52B
Interest Expense
$726.0M$934.0M$1.00B$318.0M$201.0M$183.0M$276.0M$772.0M$755.0M$971.0M$798.0M
Pretax Income
$19.80B$17.67B$18.00B$17.33B$16.50B$19.18B$19.36B$15.06B$16.69B$32.58B$17.74B
Net Income
$16.54B$1.30B$15.30B$15.12B$14.71B$20.88B$17.94B$35.15B$14.07B$26.80B$16.09B
EPS (Diluted)
5.930.475.615.635.517.816.7313.725.7911.036.60
EBITDA
$24.28B$24.25B$25.93B$24.66B$23.93B$26.75B$26.61B$23.32B$24.78B$41.05B$30.81B
Shares Out. (M)
2788.902745.302728.702684.302670.702674.002663.902560.402429.402429.402448.60

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$18.97B$17.82B$18.11B$17.30B$13.98B$14.49B$12.89B$21.86B$24.11B$19.71B$16.91B
Short-Term Investments
$22.93B$472.0M$1.58B$1.98B$11.20B$17.12B$9.39B$1.07B$417.0M$393.0M$318.0M
Total Current Assets
$65.03B$43.09B$46.03B$45.27B$51.24B$60.98B$55.29B$53.49B$55.89B$55.62B$56.35B
Total Assets
$141.21B$157.30B$152.95B$157.73B$174.89B$182.02B$187.38B$167.56B$180.10B$199.21B$197.43B
Total Current Liabilities
$26.29B$30.54B$31.23B$35.96B$42.49B$45.23B$55.80B$46.28B$50.32B$54.13B$55.46B
Long-Term Debt
$22.44B$30.68B$27.68B$26.49B$32.63B$29.98B$26.89B$25.88B$30.65B$39.44B$35.80B
Total Liabilities
$70.79B$97.14B$93.20B$98.26B$111.62B$108.00B$110.57B$98.78B$108.61B$117.67B$115.90B
Stockholders' Equity
$70.42B$60.16B$59.75B$59.47B$63.28B$74.02B$76.80B$68.77B$71.49B$81.54B$81.53B
Retained Earnings
$110.55B$101.79B$106.22B$110.66B$113.89B$123.06B$128.34B$153.84B$155.79B$168.98B$168.36B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$18.77B$21.06B$22.20B$23.42B$23.54B$23.41B$21.19B$22.79B$24.27B$24.53B$26.16B
Capital Expenditure
-$3.23B-$3.28B-$3.67B-$3.50B-$3.35B-$3.65B-$4.01B-$4.54B-$4.42B-$4.83B-$5.57B
Free Cash Flow
$15.54B$17.78B$18.53B$19.92B$20.19B$19.76B$17.18B$18.25B$19.84B$19.70B$20.59B
Investing Cash Flow
-$4.76B-$14.87B-$3.17B-$6.19B-$20.82B-$8.68B-$12.37B$878.0M-$18.60B-$23.59B-$9.34B
Financing Cash Flow
-$8.55B-$7.67B-$18.51B-$18.02B-$6.12B-$14.05B-$8.87B-$15.82B-$3.13B-$5.54B-$18.15B
Issuance of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$4.24B$0.00$0.00$3.86B
Repurchase of Stock
-$8.98B-$6.36B-$5.87B-$6.75B-$3.22B-$3.46B-$6.04B-$5.05B-$2.43B-$5.95B-$7.88B
Net Debt Issuance
$7.88B$6.75B-$3.95B-$2.88B$7.09B-$990.0M$7.45B-$2.73B$10.05B$9.64B-$787.0M
Stock Based Comp.
$878.0M$962.0M$978.0M$977.0M$1.00B$1.14B$1.14B$1.16B$1.18B$1.35B$1.42B
Net Change in Cash
$5.24B-$1.15B$283.0M-$802.0M-$3.32B$502.0M-$360.0M$7.73B$2.25B-$4.40B-$1.32B

Dilution Tracker

Shares Outstanding
2407M
5-Year Share Growth
-9.0%
Stock Issuance (TTM)
$3.86B
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
2788.902745.302728.702684.302670.702674.002663.902560.402429.402429.402448.60
Change vs Prior %
—-1.6%-0.6%-1.6%-0.5%0.1%-0.4%-3.9%-5.1%0.0%0.8%
Stock Issuance
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$4.24B$0.00$0.00$3.86B
Stock Repurchase
-$8.98B-$6.36B-$5.87B-$6.75B-$3.22B-$3.46B-$6.04B-$5.05B-$2.43B-$5.95B-$7.88B
Stock Based Comp.
$878.0M$962.0M$978.0M$977.0M$1.00B$1.14B$1.14B$1.16B$1.18B$1.35B$1.42B

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
69.7%66.7%66.8%66.4%65.6%70.3%69.3%68.8%69.1%67.9%68.8%
Operating Margin %
29.1%24.7%26.0%25.6%23.9%26.6%26.3%27.5%24.9%27.2%25.7%
Net Margin %
23.0%1.7%18.8%18.4%17.8%26.5%22.4%41.3%15.8%28.5%16.2%
EBITDA Margin %
33.8%31.7%31.8%30.0%29.0%34.0%33.3%27.4%27.9%43.6%31.0%
FCF Margin %
21.6%23.3%22.7%24.3%24.4%25.1%21.5%21.4%22.3%20.9%20.7%
ROE %
23.5%2.2%25.6%25.4%23.3%28.2%23.4%51.1%19.7%32.9%19.6%
ROA %
11.7%0.8%10.0%9.6%8.4%11.5%9.6%21.0%7.8%13.5%8.2%
ROIC %
14.6%1.1%14.5%14.9%13.0%13.8%12.3%16.6%13.8%13.7%15.4%
R&D / Revenue %
12.7%13.9%13.2%13.8%14.9%18.1%17.7%17.7%19.4%15.6%16.2%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
2.6%6.3%6.7%0.6%0.6%-4.7%1.6%6.5%4.3%6.0%
Gross Profit
3.2%1.8%6.8%0.0%-0.6%2.2%0.1%5.8%4.7%4.2%
Operating Income
14.2%-9.5%12.1%-1.0%-5.9%6.1%0.3%11.4%-5.4%15.6%
Net Income
7.3%-92.1%1076.7%-1.2%-2.7%41.9%-14.1%95.9%-60.0%90.6%
EPS (Diluted)
8.2%-92.1%1093.6%0.4%-2.1%41.7%-13.8%103.9%-57.8%90.5%
Operating Cash Flow
-2.7%12.2%5.4%5.5%0.5%-0.5%-9.5%7.5%6.5%1.1%
Free Cash Flow
-1.7%14.4%4.2%7.5%1.4%-2.1%-13.0%6.2%8.7%-0.7%
R&D Expense
1.1%15.9%1.7%5.4%8.7%15.7%-1.0%6.7%14.2%-14.9%
SG&A Expense
-5.4%7.2%4.7%-1.6%-0.4%-8.9%0.6%-0.7%9.2%7.8%
Total Assets
5.8%11.4%-2.8%3.1%10.9%4.1%2.9%-10.6%7.5%10.6%
Book Value / Share
0.8%-13.8%0.1%0.7%6.4%17.1%4.4%-7.6%9.4%13.1%
Debt
36.6%27.5%-11.9%-9.1%27.3%-4.3%17.5%-26.0%24.9%30.8%
Diluted Shares
-0.9%-1.6%-0.6%-1.6%-0.5%0.1%-0.4%-3.9%-5.1%0.0%

Valuation

P/E (TTM)41.88
10Y Low / Med / High11.29 / 24.54 / 291.08
P/S6.69
10Y Low / Med / High3.88 / 4.90 / 5.77
P/B8.29
10Y Low / Med / High4.43 / 6.09 / 6.51
EV/EBITDA22.48
10Y Low / Med / High12.97 / 16.15 / 18.36
EV/Revenue6.97
10Y Low / Med / High4.03 / 5.12 / 6.11
P/FCF32.29
10Y Low / Med / High17.39 / 21.08 / 26.87

Intrinsic Value Models (per share)

DCF Value
$295.64
Graham Number
$70.20
Cash / Share
$7.04
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
18.95291.0822.4425.4128.0021.6325.8611.2924.5418.8241.88
P/S Ratio
4.344.904.214.684.995.735.774.663.885.356.69
P/B Ratio
4.436.235.756.466.516.096.015.774.836.188.29
EV/EBITDA
13.1816.1513.7316.0018.1117.5818.3617.3514.4312.9722.48
EV/Revenue
4.455.124.364.815.255.976.114.754.035.656.97

Analyst Estimates & Quality

Altman Z-Score
5.56
Safe
Piotroski F-Score
7
Strong

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$101.22B$107.76B$116.59B
Net Income$27.15B$28.22B$33.71B
EPS$11.11$11.59$13.96
# Analysts (EPS)11125

Dividends

Dividend/Share (TTM)
$5.28
Dividend Yield
1.91%
Frequency
Quarterly
Next Payment
Dec 8, 2026

Recent Payments

Ex-DatePay DateAmountFrequency
Nov 24, 2026Dec 8, 2026$1.34Quarterly
Aug 25, 2026Sep 8, 2026$1.34Quarterly
May 26, 2026Jun 9, 2026$1.34Quarterly
Feb 24, 2026Mar 10, 2026$1.30Quarterly
Nov 25, 2025Dec 9, 2025$1.30Quarterly
Aug 26, 2025Sep 9, 2025$1.30Quarterly
May 27, 2025Jun 10, 2025$1.30Quarterly
Feb 18, 2025Mar 4, 2025$1.24Quarterly
Nov 26, 2024Dec 10, 2024$1.24Quarterly
Aug 27, 2024Sep 10, 2024$1.24Quarterly
May 20, 2024Jun 4, 2024$1.24Quarterly
Feb 16, 2024Mar 5, 2024$1.19Quarterly
Nov 20, 2023Dec 5, 2023$1.19Quarterly
Aug 25, 2023Sep 7, 2023$1.19Quarterly
May 22, 2023Jun 6, 2023$1.19Quarterly
Feb 17, 2023Mar 7, 2023$1.13Quarterly
Nov 21, 2022Dec 6, 2022$1.13Quarterly
Aug 22, 2022Sep 6, 2022$1.13Quarterly
May 23, 2022Jun 7, 2022$1.13Quarterly
Feb 18, 2022Mar 8, 2022$1.06Quarterly

Revenue Segments

By Product

Segment202020212022202320242025
Consumer$14.45B$14.63B$14.95B———
Pharmaceutical$45.17B$52.08B————
Medical Devices$22.96B$27.06B————
Innovative Medicine——$52.56B$54.76B$56.96B$60.40B
MedTech——$27.43B$30.40B$31.86B$33.79B

By Geography

Segment202020212022202320242025
Europe$18.98B$23.59B$23.45B$20.41B$20.21B$21.54B
Asia-Pacific, Africa$15.14B$17.27B$16.79B$13.76B$13.59B$14.03B
UNITED STATES$43.13B$47.16B$48.58B$46.44B$50.30B$53.75B
Western Hemisphere, excluding U.S.$5.33B$5.75B$6.13B$4.55B$4.71B$4.88B